GlassScriptPhysician profile
Launce Gouw
NPI 1689788325
$500.24
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $317 · 2020: $33.18 · 2021: $150.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Astellas Pharma US INC | $65.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $62.89 | 2019 | |
| Grifols USA, LLC | $37.89 | 2019 | |
| Amgen INC. | $37.32 | 2019 | |
| Jazz Pharmaceuticals INC. | $21.37 | 2019 | |
| Janssen Biotech, INC. | $19.58 | 2019 | |
| Abbvie INC. | $18.30 | 2019 | |
| Genzyme Corporation | $17.29 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.97 | 2019 | |
| Seagen INC. | $14.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.93 | 2019 | |
| Aurobindo Pharma USA, INC. | $12.99 | 2020 | |
| Pfizer INC. | $12.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Launce Gouw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.